Edition:
United States

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

27.82USD
21 Sep 2018
Change (% chg)

$-1.72 (-5.82%)
Prev Close
$29.54
Open
$29.43
Day's High
$29.66
Day's Low
$27.76
Volume
401,030
Avg. Vol
148,238
52-wk High
$32.99
52-wk Low
$20.16

Select another date:

Tue, May 1 2018

BRIEF-Retrophin Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S

BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis

* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:

Select another date: